CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enhancing treatment outcomes for patients with acute and chronic leukemias by utilizing next generation sequencing technologies. It aims to personalize therapies based on genetic variations among patients, ultimately identifying new biomarkers for prognosis and treatment response.
Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients.
Nowadays, the advent of high-throughput next generation sequencing (NGS) technologies that are revolutionizing genomics and transcri…
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Torino
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Verona
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Italy, ROMA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Germany, Ulm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
